Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MESOBullishCorporate Developmentsnews

High materiality9/10

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Aug 16, 2026, 8:37 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone completion reduces execution risk; RMAT designation and a potential mid-2027 BLA readout create multiple price catalysts, supported by a large addressable CLBP market and potential >$10B peak revenue.

AI summary

What happened, with direct paths to the underlying reporting

Mesoblast reports completion of patient treatment in the MSB-DR004 Phase 3 trial for rexlemestrocel-L in chronic low back pain, with 350 patients treated. The RMAT designation supports potential priority FDA review, and top-line results are due mid-2027 after the 12-month follow-up. The program targets a multibillion-dollar revenue path if approved, underscoring meaningful upside for MESO investors.

350 patients treated in MSB-DR004 Phase 3 CLBP trial.
Primary endpoint: 12-month pain reduction; trial well-powered.
RMAT designation enables priority review after BLA filing.
Top-line results expected mid-CY2027 after final 12-month follow-up.
CLBP affects 7M+ US patients; potential peak revenue >$10B.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

US FDA approves Mesoblast's cell therapy for graft-versus-host disease